ONKOSIGHT ADVANCEDTM NEXT GENERATION SEQUENCING
To learn more about our OnkoSight Advanced™ testing, please visit our GenPath website.
Empowering physicians with Advanced Genetic Sequencing to improve cancer patient management.
OnkoSight AdvancedTM, available at GenPath, a business unit of BioReference, is a next-generation sequencing (NGS) assay that enables cutting edge DNA mutational profiling of tumor samples. OnkoSight AdvancedTM focuses on only actionable mutations in common cancers. This targeted approach helps personalize patient treatment and management while greatly reducing the number of unclear variants that often occur in the results of broader NGS panels.
Genes included on OnkoSight AdvancedTM NGS panels are those with clear therapeutic, diagnostic, or prognostic value and those for which there are late-stage clinical trials available. National guidelines-recommended genes are included on each tumor-specific panel.
Critical genomic biomarkers relevant to immunotherapy; Tumor Mutation Burden (TMB) and Microsatellite Instability (MSI) are also reported with every OnkoSight AdvancedTM analysis.
To learn more about our OnkoSight Advanced™ testing, please visit our GenPath website.
Thank you for visiting ScarletHealth.com. You are being redirected to our parent organization, BioReference Health, LLC at BioReference.com, where you can view a full list of our laboratory services. We will continue to offer mobile specimen collections in specific geographic regions, in which trained phlebotomists can collect a patient’s test specimen from home or work for delivery to our laboratory for testing.
Este sitio web (y las páginas contenidas) estan desactivado. Si se necesita asistencia en español u otro idioma, por favor llame sin cargas a 800 229 5227.